Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results

TheFly reported connected January 29 that TD Cowen raised its terms people on ARDX to $13 from $10 while maintaining a Buy rating. The accommodation followed an update to the firm’s fiscal exemplary up of the ARDX’s fourth-quarter results.

Additionally, connected January 27, Jefferies besides raised its terms people connected Ardelyx, Inc. (NASDAQ:ARDX) to $15 from $8 and maintained a Buy rating. The steadfast highlighted the institution arsenic 1 of the astir underrated biotech launches and underlined sustained execution connected Ibsrela successful 2026, on with imaginable upside from IBS-C, caller CIC indications, and extended intelligence property. Peak income are present projected astatine $1.5–$2 cardinal by 2035, with further upside if the caller 2041 formulation patent proves defendable.

Ardelyx, Inc. (NASDAQ:ARDX) is simply a biopharmaceutical institution focused connected processing and commercializing first‑in‑class gastrointestinal and cardiorenal therapies. Its pb product, tenapanor, treats irritable bowel syndrome with constipation (IBS‑C) and chronic kidney disease‑related conditions.

While we admit the imaginable of ARDX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.